Long term persistence of SARS-CoV-2 humoral response in multiple sclerosis subjects

Maniscalco, Giorgia Teresa; Ferrara, Anne Lise; Liotti, Antonietta; Manzo, Valentino; Battista, Maria Elena Di; Salvatore, Simona; Graziano, Daniela; Viola, Assunta; Amato, Gerardino; Moreggia, Ornella; Cesare, Daniele Di Giulio; Alfieri, G; Iorio, Walter Di; Rocca, Gennaro Della; Andreone, Vincenzo; Rosa, Veronica De

doi:10.1016/j.msard.2022.103800

Cited by 4 publications

(8 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the anti-Spike IgG levels were significantly reduced in FTY and OCRE pwMS. The impairment observed in these two groups is in line with recent data from literature on the 3rd SARS-CoV-2 BNT162b2 mRNA vaccine booster 17 , 18 , 19 , 20 , 21 and with previous studies on the IgG titre after the 2nd SARS-CoV-2 BNT162b2 mRNA vaccine dose in pwMS under FTY and OCRE treatment [ 10 , 13 , 20 , 22 ]. Moreover, it has been shown that vaccinated COVID-19 convalescent OCRE-treated pwMS showed a humoral response comparable to healthy subjects, highlighting that SARS-CoV-2 IgG titre in OCRE-treated pwMS could be influenced by a previous SARS-CoV-2 infection [23] .…”

Section: Discussionsupporting

confidence: 91%

“…However, the kinetics of the antibody response to the vaccine in pwMS is still not well defined and, due to the persistence of the SARS-CoV-2 pandemic, booster vaccinations have been considered necessary especially for those vulnerable groups. In light of the current discussion, several studies have evaluated the duration of anti-SARS-CoV-2 immune protection in healthy individuals to schedule the right booster vaccination program 11 , 12 , 13 . In this context, clinical data suggest an attenuated short-term SARS-CoV-2 humoral response and a faster decline in pwMS receiving some DMTs while increased antibody response and persistence overtime in others 13 , 14 , 15 .…”

Section: Introductionmentioning

confidence: 99%

“…In light of the current discussion, several studies have evaluated the duration of anti-SARS-CoV-2 immune protection in healthy individuals to schedule the right booster vaccination program 11 , 12 , 13 . In this context, clinical data suggest an attenuated short-term SARS-CoV-2 humoral response and a faster decline in pwMS receiving some DMTs while increased antibody response and persistence overtime in others 13 , 14 , 15 .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Humoral efficacy of the third SARS-CoV-2 vaccine dose in Multiple Sclerosis subjects undergoing different disease-modifying therapies

Maniscalco

Liotti²,

Ferrara³

et al. 2022

Multiple Sclerosis and Related Disorders

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 91%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Humoral efficacy of the third SARS-CoV-2 vaccine dose in Multiple Sclerosis subjects undergoing different disease-modifying therapies

Maniscalco

Liotti²,

Ferrara³

et al. 2022

Multiple Sclerosis and Related Disorders

View full text Add to dashboard Cite

“…In regard to the vaccine response, some studies have found that, compared to healthy controls, SARS-CoV-2 IgG levels were similar and/or deemed adequate in people with MS treated with natalizumab, dimethyl fumarate, glatiramer acetate, cladribine, β-interferon, or teriflunomide, but impaired in people receiving ocrelizumab or fingolimod. 18,[20][21][22][27][28][29][30] Interview Another concern mentioned by Fuller was that immune modulating drugs might have a detrimental effect on the vaccine response. Shin agreed, saying: "We knew pre-pandemic that responses to vaccinations like the flu shot might be somewhat diminished by some agents, but we just said, go ahead, get vaccinated."…”

Section: Covid-19 Infection Sars-cov-2 Vaccinations and Disease Modif...mentioning

confidence: 99%

“…These studies included the array of SARS-Cov-2 vaccine types (with a higher response rate with mRNA vaccines) 42 at a number of timepoints following vaccination, up to 6 months. 18,[20][21][22][27][28][29][30]32,43 A study of booster vaccination showed increased IgG levels in patients taking fingolimod, but only two out of 29 patients had 'assumed protective humoral immunity' (IgG: >70 AU). 37 IgG levels were also not increased after a booster vaccine in a study involving 24 patients.…”

Section: Sphinogosine-1-phosphate Receptor Modulators and The Respons...mentioning

confidence: 99%

The Efficacy and Safety of SARS-CoV-2 Vaccinations in People with Multiple Sclerosis

Roberts¹

2023

EMJ Neurol

View full text Add to dashboard Cite

While people with multiple sclerosis (MS) are not more likely to contract COVID-19, the incidences of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and COVID-19-related complications may be higher for people with MS who have comorbidities or who are taking certain disease modifying therapies (DMT). Robert Shin, Professor of Neurology at MedStar Georgetown University Hospital, Washington, D.C., USA, and Deborah Fuller, Department of Microbiology, University of Washington School of Medicine, and Associate Director of the Washington National Primate Research Center, Seattle, Washington, USA, first discussed why vaccinations against SARS-CoV-2 should be recommended to people with MS. They then discussed evidence that suggests that the antibody response following vaccination may be dampened in people taking some DMTs, especially those that deplete CD20+ B cells; however, T cell responses to vaccinations may also provide protection. There is also evidence that messenger RNA (mRNA) SARS-CoV-2 vaccines, as opposed to viral vector or recombinant protein subunit vaccines, and boosters may lead to a better antibody response. Vaccine responses vary between patients taking different sphinogosine-1-phosphate (S1P) receptor modulators, being low for fingolimod and high for next generation S1P receptor modulators. Overall, more studies of vaccine response and timing are needed to best update the guidelines for people with MS.

show abstract

mRNA Vaccines against SARS-CoV-2: Advantages and Caveats

Echaide

Chocarro

Bocanegra

et al. 2023

IJMS

View full text Add to dashboard Cite

The application of BNT162b2 and mRNA-1273 vaccines against SARS-CoV-2 infection has constituted a determinant resource to control the COVID-19 pandemic. Since the beginning of 2021, millions of doses have been administered in several countries of North and South America and Europe. Many studies have confirmed the efficacy of these vaccines in a wide range of ages and in vulnerable groups of people against COVID-19. Nevertheless, the emergence and selection of new variants have led to a progressive decay in vaccine efficacy. Pfizer–BioNTech and Moderna developed updated bivalent vaccines—Comirnaty and Spikevax—to improve responses against the SARS-CoV-2 Omicron variants. Frequent booster doses with monovalent or bivalent mRNA vaccines, the emergence of some rare but serious adverse events and the activation of T-helper 17 responses suggest the need for improved mRNA vaccine formulations or the use of other types of vaccines. In this review, we discuss the advantages and limitations of mRNA vaccines targeting SARS-CoV-2 focusing on the most recent, related publications.

show abstract

Long term persistence of SARS-CoV-2 humoral response in multiple sclerosis subjects

Cited by 4 publications

References 16 publications

Humoral efficacy of the third SARS-CoV-2 vaccine dose in Multiple Sclerosis subjects undergoing different disease-modifying therapies

Humoral efficacy of the third SARS-CoV-2 vaccine dose in Multiple Sclerosis subjects undergoing different disease-modifying therapies

The Efficacy and Safety of SARS-CoV-2 Vaccinations in People with Multiple Sclerosis

mRNA Vaccines against SARS-CoV-2: Advantages and Caveats

Contact Info

Product

Resources

About